MSTN and cancer: Additionally, intervention at the activin type II receptors level via the use of the neutralizing Ab CDD866 is effective at protecting from cancer-induced cachexia as reported earlier through the blockade of circulating ligands (anti myostatin Ab or soluble ActRIIB-Fc).